Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01709487

Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Sponsor: Jules Bordet Institute

Conditions Fallopian Tube Carcinoma Ovarian Carcinoma Primary Peritoneal Carcinoma

Interventions HIPEC

Updated 5 times since 2017 Last updated: Feb 23, 2016 Started: May 31, 2010 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Fallopian Tube Carcinoma and Ovarian Carcinoma and is currently completed. Jules Bordet Institute leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jules Bordet Institute

Data source: Jules Bordet Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brussels, Belgium
• Liège, Belgium